Answering TTP Foundation is looking to collect information about TTP treatment across Canada. Both patients (or their loved one), and TTP Treaters (physicians and nurses) are encouraged to take part. This short survey will take only 5 minutes of your time.
This is your opportunity to help the entire community learn from your experiences. Information collected through this survey, will help the Foundation shape next steps to ensure access to best treatment options. In particular, if you have had experience with caplacizlumab we would love the opportunity to learn from you. Caplacizumab is the first targeted treatment approved in Canada for the treatment of TTP.
If you are a patient, or filling out a survey on behalf of a patient, please limit to one response per patient. Survey closes March 23.